LGND$191.39
$190.02
Chart
Performance
Key Stats
AI LGND Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyLigand Pharmaceuticals (LGND) shows a mixed but generally positive outlook. While the company has strong fundamental backing with a diversified portfolio and a low-cost structure, its current technical indicators suggest some caution. The thematic potential in the biopharmaceutical sector remains strong, but investors should be aware of the recent negative EPS and net margin. The upcoming earnings report will be a key event to watch.
Thematic
Ligand Pharmaceuticals operates within the robust biopharmaceutical sector, which is driven by ongoing innovation, an aging global population, and increasing healthcare spending. The company's focus on licensing technologies and acquiring royalty rights positions it to benefit from drug development successes across various therapeutic areas.
Fundamental
Ligand Pharmaceuticals exhibits a strong balance sheet and efficient operations, but recent financial performance shows profitability challenges. While revenue growth is positive, the company has reported losses and negative net margins.
Technical
LGND's technical indicators present a mixed picture. While longer-term moving averages suggest a bullish trend, shorter-term oscillators indicate potential overbought conditions or a neutral stance, advising caution for short-term traders.
| Factor | Score |
|---|---|
| Biopharmaceutical Industry Growth | 85 |
| Diversified Product Portfolio | 80 |
| Partnerships with Major Pharma | 85 |
| Technological Platforms (Captisol, NITRICIL) | 70 |
| Regulatory Landscape | 55 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 20 |
| Growth | 75 |
| Balance Sheet Health | 95 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 55 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Earnings Surprise Trend
The company has consistently beaten EPS estimates for the last three quarters, with surprises of 10.83%, 6.72%, and 36.66% respectively. This indicates a pattern of exceeding expectations.
Strong Price-to-Sales (P/S) Ratio
The Price/Sales (P/S) ratio of 18.3 (TTM) and 48.3 (2024Q4) suggests strong market demand and pricing power relative to revenue. However, this needs to be viewed in context of the biotechnology sector where high P/S ratios are not uncommon due to the long-term potential of drug pipelines.
Bearish Points (6)
Negative Net Income and Margins
The company reported a net loss of $4.03M for the full year 2024 with a net margin of -2.4%. Quarterly results also show significant net losses in Q1, Q2, and Q4 of 2024, with very high negative net margins (-93.6%, -125.0%, -72.6% respectively). This indicates a lack of profitability.
High Valuation Multiples Amidst Losses
The trailing Price-to-Earnings (P/E) ratio is -31.8, and for 2024 it's -512.7, reflecting the company's current unprofitability. While P/S ratios are high, the negative earnings make traditional P/E valuation unreliable and suggest a high risk for investors if the company cannot achieve profitability.
Calendar
July 2010
2
Ex-Dividend Date
August 2025
7
Next Earnings Date
H: $1.73
A: $1.42
L: $1.27
H: 48.29M
A: 43.87M
L: 38.07M
Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Seasonals
Price Target
143.88 USD
The 39 analysts offering 1 year price forecasts for LGND have a max estimate of 157.00 and a min estimate of 135.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor with a similar technology licensing and royalty-based business model, focusing on drug delivery technologies. [2]
Weight: 90
Identified as a key competitor of LGND, often compared on financial metrics. [2]
Weight: 85
Competitor in the biopharmaceutical space, focusing on bioprocessing technologies which can involve licensing. [2]
Weight: 80
Competitor focused on RNA-targeted therapeutics, a field highly reliant on strategic partnerships and licensing agreements. [2]